Medical Marijuana, Inc.’s HempMeds® Mexico Sponsors Cross-Border Forum, U.S. Representatives and Mexican Political Candidates Set to Discuss Rights to Patient Access

As Mexico’s Marijuana Laws Become More Defined, Legal Experts Join Medical Professionals and Patient Advocates at Public Forum on Marijuana Use April 2 at Marriott Tijuana

SAN DIEGO, March 31, 2016 (GLOBE NEWSWIRE) — Medical Marijuana, Inc., (OTC PINK:MJNA) is proud to announce to shareholders and the public that portfolio company HempMeds® Mexico is sponsoring a cross-border effort to discuss new perspectives on cannabis and legal access in Mexico.

Former California Assembly member Lori Saldaña and San Diego council member David Álvarez will join Tijuana government officials at the April 2 meeting, which will take place at the Hotel Marriott Tijuana located at Blvd. Agua Caliente 11553, col. Aviacion, Tijuana, from 10 a.m.-6 p.m. Patients and government officials from Tijuana and California will also participate in the public forum.

Presenting on the rapidly evolving global cannabis industry is Dr. Stuart W. Titus, Chief Executive Officer of Medical Marijuana, Inc., who in February educated Mexican and international healthcare practitioners on cannabis’ anti-aging benefits in Mexico City. At the Tijuana event, Titus will explain aspects of the endocannabinoid system and the effects of cannabidiol (CBD) on a wide array of conditions expressed in the U.S. Department of Health and Human Services’ patent 6630507 “Cannabinoids as Anti-Oxidants and Neuroprotectants.”

During the event, a special presentation about cannabis and human rights will feature experts explaining how Mexican families won the first-ever import permits for Medical Marijuana, Inc.’s RSHO-X™.

Finally Mayela Benavides, mother of Grace Elizalde, will discuss her daughter’s story. Elizalde advocates for the impact that cannabinoid-based therapies have and will specifically discuss the product RSHO-X™, which is the first legally accessible CBD-based product in Mexico available by doctor’s prescription and special import permit.

Representatives from HempMeds® Mexico will explain RSHO-X™ products specifically available to consumers with a doctor’s recommendation and special permit from COFEPRIS in Mexico including:

  • Real Scientific Hemp Oil-X™ Gold Label CBD Hemp Oil in the 10 gram oral applicator contains 2,500mg cannabidiol
  • Real Scientific Hemp Oil-X™ Liquid Gold Label CBD Hemp Oil in 4 fl. oz. bottle contains 1,000mg cannabidiol
  • Real Scientific Hemp Oil-X™ Liquid Gold Label CBD Hemp Oil in 8 fl. oz. bottle contains 5,000mg cannabidiol

For information on RSHO-X™ product availability in Mexico, visit the HempMeds® Mexico website at or, to speak with a HempMeds® Mexico representative, contact the customer service department at:
US: 1-866-786-2440
MX: 001-883-786-2440

About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company, created to provide access to cannabinoid-based products including cannabidiol (CBD) hemp oil products as they become legal in the country of Mexico for the first time. Our Company is a sales, marketing and distribution company. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to our CBD hemp oil products. HempMeds® Mexico is the first company to legally ship RSHO-XTM CBD hemp oil into Mexico. For more information, please review the company’s website at:

About HempMeds®
HempMeds® offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink:MJNA) and the Company’s exclusive master distributor and contracted marketing company. In addition to handling sales and distribution, HempMeds® is the communication hub for the Medical Marijuana Inc. portfolio of companies.

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.